Esperion acquires Corstasis for $83.4M, financed via $25M loan and $50M royalty sale

Esperion Therapeutics, Inc.

Total acquisition cost $83.4M: $77.5M cash to Corstasis plus $5.9M direct transaction costs.
Acquired developed product intangible Enbumyst valued at $77.1M, amortized over 10 years.
Financing: $25M term loan at 9.75% (effective ~10.5%) and $50M royalty sale to Athyrium with $100M cap.
Pro forma net loss for 2025 increases to $47.1M from $22.7M historical; no goodwill recognized.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.